sls009
Generic: tambiciclib·Code: SLS009
sls009: developed by 1 company · 1 clinical trial tracked.
sls009 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect sls009 to SLS; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could sls009 → SLS affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase I/IIa, Open-Label Dose Escalation and Dose Expansion Study of Intravenous GFH009 Single Agent and in Combination With Venetoclax and Azacitidine in Patients With Relapsed/Refractory Hematologic Malignancies and High-Risk Newly Diagnosed AML
Primary endpoint: Safety and Tolerability: Dose Limiting Toxicities (DLTs)
InterventionalRandomizedopen160 targetStarted 2021-05Completion 2027-1226 sites · China, United StatesSellas Life Sciences Group
Frequently asked questions
Who is developing sls009?
sls009 is being developed by SELLAS Life Sciences Group, Inc..
How many clinical trials involve sls009?
BioSniper tracks 1 clinical trial involving sls009.